MRUS
Merus N.V.
Set alert
52-week range unavailable
- YTD
- 0.00%
- 1 year
- +112.77%
- Open
- 90.00
- Prev close
- 90.00
- Mkt cap
- 6.83B
- Vol
- 2.72M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 90.00
- High
- 90.00
- Forward P/E
- -17.65
- Beta
- 1.06
- Short ratio
- 0.59
- Inst. own
- 92.80%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 95.41
- 200-d avg
- 69.34
- 1y target
- 97.00
Key statistics
- Market cap
- 6.83B
- Enterprise value
- 6.20B
- Trailing P/E
- 0.00
- Forward P/E
- -17.65
- PEG ratio
- 0.00
- Price / sales
- 120.59
- Price / book
- 8.81
- EPS (TTM)
- -5.28
- Beta
- 1.06
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 56.61M
- Revenue growth
- 3.20%
- Free cash flow
- -174.43M
- Total cash
- 635.93M
- Total debt
- 12.32M
- Return on equity
- -51.57%
- Shares outstanding
- 75.85M
- Short % of float
- 1.08%
- 50-day average
- 95.41
- 200-day average
- 69.34
Analyst view
Consensus: hold
- Strong buy0
- Buy1
- Hold9
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.99344.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 6, 2025 | Leerink Partners | down | Outperform | Market Perform |
| Sep 30, 2025 | Guggenheim | down | Buy | Neutral |
| Sep 30, 2025 | Canaccord Genuity | down | Buy | Hold |
| Sep 30, 2025 | Wells Fargo | down | Overweight | Equal-Weight |
| Sep 30, 2025 | UBS | down | Buy | Neutral |
| Sep 30, 2025 | LifeSci Capital | down | Outperform | Market Perform |
About Merus N.V.
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. As of December 11, 2025, Merus N.V. operates as a subsidiary of Genmab A/S.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Netherlands
- Website
- merus.nl
News
- LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update
- Merus Power Delivers an Energy Storage System for Extreme Arctic Conditions
- Federated Hermes Inc. Sells 279,425 Shares of Merus N.V. $MRUS
- Merus N.V. (NASDAQ:MRUS) Receives Average Recommendation of “Hold” from Analysts
- Market Today: Tesla dethroned; Wall St. starts 2026 higher
- First Look: Futures Climb, FTSE 10,000, BYD Tops Tesla
- First Look: 2026 Outlook, Buffett Exit, Fed Split, Dollar Slide
- A/S Genmab Buys 2,978 Shares of Merus (NASDAQ:MRUS) Stock
- Market Today: Buffett era ends; Tesla warns; stocks cap strong 2025
- Merus (NASDAQ:MRUS) Major Shareholder A/S Genmab Buys 15,710 Shares
Your note
Sign in to keep a note on MRUS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKKER LEX B H | Officer | Conversion of Exercise of derivative security | Jul 1, 2021 | 15,668 |
| BVF PARTNERS L P | Beneficial Owner of more than 10% of a Class of Security | Sale | Jul 1, 2021 | 0 |
| BVF PARTNERS L.P. | Beneficial Owner of more than 10% of a Class of Security | Sale | Oct 7, 2021 | 0 |
| DE KRUIF JOHN | Chief Technology Officer | Sale | Aug 11, 2021 | 15,282 |
| GENMAB AS | Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 25, 2025 | 0 |
| IWICKI MARK T. | Director | Conversion of Exercise of derivative security | Apr 13, 2023 | 73,576 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 5.77% | 4,373,770 | 393.64M | Sep 29, 2025 |
| Avoro Capital Advisors LLC | 4.67% | 3,542,500 | 318.82M | Sep 29, 2025 |
| Commodore Capital Lp | 4.65% | 3,525,000 | 317.25M | Sep 29, 2025 |
| Deerfield Management Company, L.P | 4.02% | 3,046,916 | 274.22M | Sep 29, 2025 |
| HBK Investments L P | 3.76% | 2,850,000 | 256.50M | Sep 29, 2025 |
| FMR, LLC | 3.71% | 2,810,935 | 252.98M | Sep 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund | 0.84% | 640,000 | 57.60M | Oct 30, 2025 |
| Fidelity Rutland Square TRT II-Strategic Advisers U.S. Total Stock Fd. | 0.82% | 620,890 | 55.88M | Sep 29, 2025 |
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund | 0.78% | 593,000 | 53.37M | Oct 30, 2025 |
| Columbia Funds Series Trust I-Columbia Cornerstone Growth Fund | 0.67% | 509,004 | 45.81M | Oct 30, 2025 |
| SmallCap World Fund Inc | 0.65% | 491,244 | 44.21M | Sep 29, 2025 |
| iShares Trust-iShares Biotechnology ETF | 0.54% | 412,869 | 37.16M | Oct 30, 2025 |